Minute ventilation/carbon dioxide production in chronic heart failure.

Publication Year: 2021

DOI:
10.1183/16000617.0141-2020

PMCID:
PMC9489123

PMID:
33536259

Journal Information

Full Title: Eur Respir Rev

Abbreviation: Eur Respir Rev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest: P. Agostoni reports non-financial support from Menarini, grants from Daiichi Sankyo and Bayer; non-financial support from Novartis and Boehringer; and grants and non-financial support from Actelion, outside the submitted work.: Conflict of interest: S. Sciomer has nothing to disclose.: Conflict of interest: P. Palermo reports personal fees from Novartis and Malesci, outside the submitted work.: Conflict of interest: M. Contini reports personal fees and non-financial support from Dompé Farmaceutici S.p.A. and personal fees from Novartis, outside the submitted work.: Conflict of interest: B. Pezzuto has nothing to disclose.: Conflict of interest: S. Farina has nothing to disclose.: Conflict of interest: A. Magini has nothing to disclose.: Conflict of interest: F. De Martino has nothing to disclose.: Conflict of interest: D. Magrì has nothing to disclose.: Conflict of interest: S. Paolillo has nothing to disclose.: Conflict of interest: G. Cattadori has nothing to disclose.: Conflict of interest: C. Vignati has nothing to disclose.: Conflict of interest: M. Mapelli has nothing to disclose.: Conflict of interest: A. Apostolo has nothing to disclose.: Conflict of interest: E. Salvioni has nothing to disclose."

Evidence found in paper:

"Conflict of interest: P. Agostoni reports non-financial support from Menarini, grants from Daiichi Sankyo and Bayer; non-financial support from Novartis and Boehringer; and grants and non-financial support from Actelion, outside the submitted work."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025